A multi-center open-label parallel group randomized controlled trial to compare iGlarLixi versus premixed insulin in patients with type 2 diabetes who have failed to achieve glycemic control with basal insulin and oral antidiabetic agents

drug protocol number
LPS15017
drug sponsor
Sanofi
drug study
HOE901 (insulin glargine)/ AVE0010 (lixisenatide) combination
drug trial site
KFMC
drug status
Ongoing
drug phase